4/25/2013

DSM Pharmaceutical Products agreed to develop DecImmune Therapeutics' monoclonal antibody program. DecImmune is working on an antibody-based drug to block activation of the N2 neoepitope and protect tissues and organs. Beginning development activities will be carried out at DSM Biologics' plant in Groningen, Netherlands.

Related Summaries